{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:43:54Z","timestamp":1762868634995,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: Biological treatment is an important and effective therapy for psoriasis. During the COVID-19 pandemic, it remains unclear whether this type of therapy affects the course of SARS-CoV-2 infection. The aim of the study was to observe patients with psoriasis undergoing biological or other systemic treatment in relation to the impact of SARS-CoV-2 infection on the course of psoriasis and the COVID-19 disease itself. Materials and methods: A one-year observational study included 57 patients with diagnosed psoriasis who qualified for biological treatment and a group of 68 similar patients who were administered a different systemic treatment. Patients were analyzed monthly for psoriasis (including Psoriasis Area Severity Index (PASI) assessment) and constantly for SARS-CoV-2 infection (telephone contact). Cases of COVID-19 were confirmed by Polymerase Chain Reaction (PCR) at the study center. Results: SARS-CoV-2 infection was confirmed by a positive Real Time Polymerase Chain Reaction (RT-PCR) test in eight patients (14.0%) with psoriasis on biological therapy. None of the cases in this group required hospitalization for COVID-19. Similar data were obtained in the control group. Specifically, 11 (16%) patients were confirmed to be infected with SARS-CoV-2. These results were statistically comparable (p &gt; 0.05). In the group of patients undergoing biological treatment, six (75%) of eight patients developed an exacerbation of psoriasis during SARS-CoV-2 infection, and similar results were noted in the control group, with eight (72%) patients experiencing an exacerbation of psoriasis. Conclusions: Patients with psoriasis who were administered biological treatment or other systemic therapy may experience a mild course of SARS-CoV-2 infection but might also experience a temporary exacerbation of skin lesions.<\/jats:p>","DOI":"10.3390\/medicina57090881","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:49:51Z","timestamp":1630363791000},"page":"881","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0954-7390","authenticated-orcid":false,"given":"Magdalena","family":"Mroz","sequence":"first","affiliation":[{"name":"Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szymon","family":"Mu\u0107ka","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyna","family":"Miodo\u0144ska","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Ziolkowska","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Hadas","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-2263","authenticated-orcid":false,"given":"Andrzej","family":"Bo\u017cek","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Disease, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"ref_1","unstructured":"Braun-Falco, O., Burgdorf, W.H.C., Plewig, G., Wolff, H.H., and Landthaler, M. (2009). Dermatology. Psoriasis, Springer. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e13298","DOI":"10.1111\/dth.13298","article-title":"COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/09546634.2020.1764904","article-title":"A challenging case of psoriasis flare-up after COVID-19 infection","volume":"31","author":"Nasiri","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e13383","DOI":"10.1111\/dth.13383","article-title":"A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?","volume":"33","author":"Kutlu","year":"2020","journal-title":"Dermatol Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13632","DOI":"10.1111\/dth.13632","article-title":"Covid-19 and exacerbation of psoriasis","volume":"33","author":"Ozaras","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105982","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14712598.2021.1853698","article-title":"Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study","volume":"21","author":"Talamonti","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000513575","article-title":"Biologic Therapies, Psoriasis i COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II","volume":"237","author":"Camela","year":"2021","journal-title":"Dermatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102613","DOI":"10.1016\/j.jaut.2021.102613","article-title":"Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies\u2014A Danish population-based cohort study","volume":"118","author":"Attauabi","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_13","first-page":"e14700","article-title":"Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience","volume":"34","author":"Pehlivan","year":"2021","journal-title":"Dermatol Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mease, P.J., Calabrese, L.H., Duffin, K.C., Haberman, R.H., Firmino, R., Scher, J.U., Schick, L., Winthrop, K., and Merola, J.F. (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session from the GRAPPA 2020 Annual Meeting. J. Rheumatol.","DOI":"10.3899\/jrheum.201671"},{"key":"ref_15","unstructured":"(2021, March 01). Announcement of the Polish Society of Rheumatology and the National Consultant in the Field of Rheumatology for Patients and Doctors in Connection with the Spreading COVID-19 Infection Based on the Eular Guidelines of 17\/03\/2020. Available online: https:\/\/www.eular.org\/recommendations_management.cfm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaad.2020.09.001","article-title":"National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease during the Pandemic: Version 1","volume":"83","author":"Gelfand","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e770","DOI":"10.1111\/jdv.16841","article-title":"Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy","volume":"34","author":"Talamonti","year":"2020","journal-title":"Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Miodo\u0144ska, M., Bogacz, A., Mr\u00f3z, M., Mu\u0107ka, S., and Bo\u017cek, A. (2021). The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients. Medicina, 22.","DOI":"10.3390\/medicina57060521"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/881\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:08Z","timestamp":1760165588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090881"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090881","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}